NASDAQ: ADTXAditxt Inc Stock
$0.90-0.09 (-9.09%)
Updated Mar 17, 2023
ADTX Price
$0.90
Fair Value Price
$7.45
Market Cap
$3.75M
52 Week Low
$0.90
52 Week High
$28.49
P/E
-0.01x
P/B
0.3x
P/S
5.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$853.15k
Earnings
-$43.52M
Gross Margin
20.9%
Operating Margin
-5,011.75%
Profit Margin
-5,101%
Debt to Equity
0.51
Operating Cash Flow
-$24M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ADTX Overview
Aditxt, Inc. is a biotech company developing technologies to improve the health of the immune system by mapping and reprogramming. Its products, AditxtScore and Apoptotic DNA Immunotherapy, mimic the way the body naturally induces tolerance. Aditxt is also developing organ transplant products. The company has a license agreement with Loma Linda University. It was known as ADiTx Therapeutics, Inc. until it changed its name in 2021/07. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, VA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADTX ($0.90) is undervalued by 87.92% relative to our estimate of its Fair Value price of $7.45 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ADTX ($0.90) is significantly undervalued by 87.92% relative to our estimate of its Fair Value price of $7.45 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ADTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ADTX due diligence checks available for Premium users.
Be the first to know about important ADTX news, forecast changes, insider trades & much more!
ADTX News
Valuation
ADTX fair value
Fair Value of ADTX stock based on Discounted Cash Flow (DCF)
Price
$0.90
Fair Value
$7.45
Undervalued by
87.92%
ADTX ($0.90) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ADTX ($0.90) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ADTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ADTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
16.18x
Market
21.81x
ADTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.3x
Industry
4.75x
ADTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADTX's financial health
Profit margin
Revenue
$323.1k
Net Income
-$7.6M
Profit Margin
-2,338.9%
ADTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ADTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$19.2M
Liabilities
$6.5M
Debt to equity
0.51
ADTX's short-term assets ($12.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADTX's short-term assets ($12.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.8M
Investing
$87.4k
Financing
$16.2M
ADTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADTX vs Biotech Stocks
Aditxt Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.